Objective To compare the efficacy of covid-19 vaccines between immunocompromised and
immunocompetent people. Design Systematic review and meta-analysis. Data sources …

Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19 …

SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …

Objective To provide guidance to rheumatology providers on the use of coronavirus disease
2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases …

Background B-cell-depleting therapies increase the risk of morbidity and mortality due to
COVID-19. Evidence-based SARS-CoV-2 vaccination strategies for patients on B-cell …

Novel mRNA-based vaccines have been proven to be powerful tools in combating the
global pandemic caused by SARS-CoV-2, with BNT162b2 (trade name: Comirnaty) …

Concerns for anaphylaxis may hamper severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) immunization efforts. We convened a multidisciplinary group of international …

Objectives The treatment for COVID-19 often utilizes immune-modulating drugs. These
drugs are also used in immune mediated inflammatory diseases (IMIDs). We performed a …

Objectives Evidence suggests that B cell-depleting therapy with rituximab (RTX) affects
humoral immune response after vaccination. It remains unclear whether RTX-treated …

Background Patients on therapeutic immunosuppressants for immune-mediated
inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to …